uniQure (NASDAQ:QURE) Shares Gap Down – Should You Sell?

uniQure N.V. (NASDAQ:QURE)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $15.94, but opened at $15.55. uniQure shares last traded at $15.8660, with a volume of 164,692 shares changing hands.

Analyst Ratings Changes

Several brokerages have weighed in on QURE. Barclays started coverage on uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of uniQure in a research report on Tuesday, March 10th. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Wolfe Research assumed coverage on shares of uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Finally, The Goldman Sachs Group reduced their target price on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.25.

uniQure Trading Down 2.1%

The business’s 50 day moving average price is $21.24 and its two-hundred day moving average price is $29.68. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The company has a market capitalization of $975.41 million, a price-to-earnings ratio of -4.52 and a beta of 0.73.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. Equities analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. The trade was a 23.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 81,399 shares of company stock worth $1,527,645 in the last quarter. Company insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the business. Private Trust Co. NA bought a new position in shares of uniQure during the 3rd quarter valued at about $28,000. Torren Management LLC bought a new stake in shares of uniQure in the 4th quarter worth approximately $28,000. Jones Financial Companies Lllp raised its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc acquired a new stake in uniQure during the fourth quarter valued at approximately $48,000. Finally, Smartleaf Asset Management LLC acquired a new stake in uniQure during the fourth quarter valued at approximately $48,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.